215 related articles for article (PubMed ID: 16912520)
1. [The incidence and management of bone metastasis from breast cancer].
Saeki T; Ookubo K; Takeuchi H; Fujiuchi N
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1054-7. PubMed ID: 16912520
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates--role in cancer therapies.
Mehrotra B
J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):19-26. PubMed ID: 19371811
[No Abstract] [Full Text] [Related]
3. [Bone targeting agents: bisphosphonates].
Debiais F
Bull Cancer; 2013 Nov; 100(11):1199-206. PubMed ID: 24158668
[TBL] [Abstract][Full Text] [Related]
4. [Bisphosphonates and breast cancer].
Vehmanen L; Saarto T
Duodecim; 2010; 126(10):1229-37. PubMed ID: 20597352
[TBL] [Abstract][Full Text] [Related]
5. [Current use of bisphosphonates in clinical oncology].
Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V
Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372
[TBL] [Abstract][Full Text] [Related]
6. Effect of oral bisphosphonates for osteoporosis on development of skeletal metastases in women with breast cancer: results from a pharmaco-epidemiological study.
Kremer R; Gagnon B; Meguerditchian AN; Nadeau L; Mayo N
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25278509
[TBL] [Abstract][Full Text] [Related]
7. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
[TBL] [Abstract][Full Text] [Related]
8. Treatment options for breast cancer and bone metastases.
Pecherstorfer M
Womens Health (Lond); 2009 Mar; 5(2):149-63. PubMed ID: 19245353
[TBL] [Abstract][Full Text] [Related]
9. Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease.
Heidenreich A; Ohlmann CH
Expert Rev Anticancer Ther; 2004 Dec; 4(6):991-1005. PubMed ID: 15606328
[TBL] [Abstract][Full Text] [Related]
10. [Bisphosphonates in the therapy of cancer patients].
Jantunen E; Kumpulainen E
Duodecim; 1999; 115(1):27-32. PubMed ID: 11830857
[No Abstract] [Full Text] [Related]
11. Bisphosphonates in the prevention and treatment of bone metastases.
Ramaswamy B; Shapiro CL
Oncology (Williston Park); 2003 Sep; 17(9):1261-70; discussion 1270-2, 1277-8, 1280. PubMed ID: 14569853
[TBL] [Abstract][Full Text] [Related]
12. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
Facchini G; Caraglia M; Santini D; Nasti G; Ottaiano A; Striano S; Maiolino P; Ruberto M; Fiore F; Tonini G; Budillon A; Iaffaioli RV; Zeppetella GL
J Exp Clin Cancer Res; 2007 Sep; 26(3):307-12. PubMed ID: 17987788
[TBL] [Abstract][Full Text] [Related]
13. Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
Paterson AH; Kanis JA; Powles TJ; McCloskey E; Hanson J; Ashley S
Can J Oncol; 1995 Dec; 5 Suppl 1():54-7. PubMed ID: 8853526
[TBL] [Abstract][Full Text] [Related]
14. Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis.
Ding X; Fan Y; Ma F; Li Q; Wang J; Zhang P; Yuan P; Xu B
Breast; 2012 Aug; 21(4):544-9. PubMed ID: 22627092
[TBL] [Abstract][Full Text] [Related]
15. [Bisphosphonate treatment against breast cancer with bone metastases].
Kohno N
Nihon Rinsho; 2007 Jun; 65 Suppl 6():575-81. PubMed ID: 17682213
[No Abstract] [Full Text] [Related]
16. Clinical trials in metastatic breast cancer to bone: past--present--future.
Body JJ
Can J Oncol; 1995 Dec; 5 Suppl 1():16-27. PubMed ID: 8853520
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapy of bone metastases in breast cancer patients.
Petrut B; Simmons C; Broom R; Trinkaus M; Clemons M
Expert Opin Pharmacother; 2008 Apr; 9(6):937-45. PubMed ID: 18377337
[TBL] [Abstract][Full Text] [Related]
18. Improving the use of intravenous bisphosphonates in women with breast cancer metastatic to bone.
Mortimer J; Mendelsohn M
J Natl Compr Canc Netw; 2014 Feb; 12 Suppl 1():S40-1. PubMed ID: 24614052
[TBL] [Abstract][Full Text] [Related]
19. Long-term benefits versus side-effects from bone-targeted therapies for cancer patients: minimizing risk while maximizing benefits.
Jacobs C; Ng T; Ong M; Clemons M
Curr Opin Support Palliat Care; 2014 Dec; 8(4):420-8. PubMed ID: 25121618
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
